Education
About Us
Working with TipRanks
Follow Us
XOMA Royalty Corporation (XOMA)
NASDAQ:XOMA
XOMA Stock Chart & Stats
$26.38
$0.08(0.31%)
At close: 4:00 PM EST
$26.38
$0.08(0.31%)
Day’s Range― - ―
52-Week Range$18.35 - $39.92
Previous CloseN/A
Volume8.24K
Average Volume (3M)53.64K
Market Cap
$326.67M
Enterprise Value$368.10M
Total Cash (Recent Filing)$92.00M
Total Debt (Recent Filing)$131.91M
Price to Earnings (P/E)8.3
Beta1.33
Next Earnings
Mar 18, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.70
Shares Outstanding12,383,103
10 Day Avg. Volume49,949
30 Day Avg. Volume53,642
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)3.75
Price to Sales (P/S)10.79
P/FCF Ratio-22.33
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue7.81
Enterprise Value/Gross Profit8.34
Enterprise Value/Ebitda32.57
Forecast
1Y Price Target
$73.50Price Target Upside178.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.67
Revenue Forecast (FY)$64.02M
Bulls Say, Bears Say
Bulls Say
Generation Bio Acquisition And Technology ExposureAcquisition of Generation Bio provides exposure to its ctLNP delivery platform and an existing collaboration with Moderna, creating potential opportunities for outlicensing, milestones, or future royalties.
Non-dilutive Deal-making StrategyManagement's use of creative, low-cash transactions to acquire royalty and licensing assets preserves equity and increases optionality for future revenue from partnered programs.
Takeda Deal Expands Royalty PortfolioExpanded agreement with Takeda delivers royalty interests across nine additional assets, broadening potential milestone and royalty streams without a cash outlay.
Bears Say
Clinical Trial Failure At RezoluteRezolute's Phase 3 study of ersodetug missed both primary and secondary endpoints, removing a potential revenue driver and increasing uncertainty around regulatory and commercial prospects.
Partner Liquidity And Cash Burn RiskHigh cash burn at partners led to an acquisition in one case, highlighting that partner funding shortfalls can limit future royalty potential and force value-destructive transactions.
Revenue Visibility And Near-term Earnings PressureRemoval of an expected revenue driver from reported results reduces revenue visibility and could pressure the stock while replacement royalty streams are established.
XOMA Royalty Corporation News
XOMA FAQ
What was XOMA Royalty Corporation’s price range in the past 12 months?
XOMA Royalty Corporation lowest stock price was $18.35 and its highest was $39.92 in the past 12 months.
What is XOMA Royalty Corporation’s market cap?
XOMA Royalty Corporation’s market cap is $326.67M.
When is XOMA Royalty Corporation’s upcoming earnings report date?
XOMA Royalty Corporation’s upcoming earnings report date is Mar 18, 2026 which is in 2 days.
How were XOMA Royalty Corporation’s earnings last quarter?
XOMA Royalty Corporation released its earnings results on Nov 12, 2025. The company reported $0.7 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.74.
Is XOMA Royalty Corporation overvalued?
According to Wall Street analysts XOMA Royalty Corporation’s price is currently Undervalued.
Does XOMA Royalty Corporation pay dividends?
XOMA Royalty Corporation does not currently pay dividends.
What is XOMA Royalty Corporation’s EPS estimate?
XOMA Royalty Corporation’s EPS estimate is -0.12.
How many shares outstanding does XOMA Royalty Corporation have?
XOMA Royalty Corporation has 12,383,103 shares outstanding.
What happened to XOMA Royalty Corporation’s price movement after its last earnings report?
XOMA Royalty Corporation reported an EPS of $0.7 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went down -2.522%.
Which hedge fund is a major shareholder of XOMA Royalty Corporation?
Currently, no hedge funds are holding shares in XOMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
XOMA Royalty Corporation Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$73.50 (178.62% Upside)
$73.50 (178.62% Upside)
Hedge Fund Trend
Increased
By 53.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.28%
12-Months-Change
Fundamentals
Return on Equity
16.22%
Trailing 12-Months
Asset Growth
-8.15%
Trailing 12-Months
Company Description
XOMA Royalty Corporation
XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
XOMA Stock 12 Month Forecast
Average Price Target
$73.50
▲(178.62% Upside)
Technical Analysis
Ocugen
―
Corvus Pharmaceuticals
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
13.18% Insiders
17.85% Mutual Funds
28.72% Other Institutional Investors
32.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---